Armin Hofmeister

Medicinal Chemist in Oligonucleotide Drug Discovery

Mölndal, Västra Götaland County, Sweden

About

Experience

  • Senior Principal Scientist in Medicinal Chemistry at Ribocure Pharmaceuticals AB
    Jan 2026 - Present · 7 mos

  • Associate Director - Exploratory Chemistry at Dewpoint Therapeutics
    Jan 2023 - Sep 2025 · 2 yrs 9 mos

    Design and synthesis of single stranded oligonucleotides targeting protein binding motifs in condensate-relevant RNAs. Development of novel chemically modified PMO-nucleotides for the optimization of oligonucleotide potency and delivery. Synthesis of chemically modified oligonucleotides for secondary structure optimization.

  • Principal Scientist at AstraZeneca Early R&I New Modalities Chemistry at AstraZeneca
    Feb 2021 - Dec 2022 · 1 yr 11 mos

    Development of targeting and delivery strategies for oligonucleotide modalities into the lung. Development of siRNA- and ASO-conjugates, targeting specific lung cell lines. Lead finding and optimization of antisense oligonucleotides as therapeutic modalities in lung diseases.

  • Sanofi (21 yrs 11 mos)
    • Head of Laboratory in Medicinal Chemistry
      Jul 2020 - Jan 2021 · 7 mos

      Classical Medicinal Chemistry in a lead optimization program on small molecule kinase inhibitors.

    • Head of Laboratory in Nucleic Acid Chemistry
      May 2010 - Jun 2020 · 10 yrs 2 mos

      Syntheses of novel nucleotide scaffolds and their use in oligonucleotide optimization. Development of an inhouse IP on hepatic siRNA-targeting. Project lead on the identification of novel small molecule ligands for siRNA-targeting. Chemical lead in therapeutic siRNA-projects. Responsible for scientific collaborations with partners from academia and biotech companies. Author and co-author of several patent applications and publications on novel nucleotide analogs and hepatic siRNA-targeting.

    • Head of Laboratory in Medicinal Chemistry
      Mar 1999 - Apr 2010 · 11 yrs 2 mos

      Classical Medicinal Chemistry in lead finding and optimization programs based on HTS-approaches, rational drug design and rescaffolding of literature compounds. Project lead and chemical lead in small molecule optimization programs on ion channels, kinases and proteases. Author and co-author of more than 35 patent applications and scientific publications on small molecule programs.

  • Johannes Gutenberg-Universität Mainz ()
    • PhD Student
      Apr 1995 - Dec 1998 · 3 yrs 9 mos

      PhD in Natural Sciences PhD thesis in the research group of Prof. H. Kunz at the Institute of Organic Chemistry: "Carbohydrate substituted cyclopentadienes for the syntheses of chiral metallocenes". High experience in carbohydrate chemsitry and asymmetric catalysis.

    • Student of Chemical Sciences
      Oct 1989 - Mar 1995 · 5 yrs 6 mos

      Diploma in Chemistry Diploma thesis in the research group of Prof. H. Kunz at the Institute of Organic Chemistry: "Carbohydrate substituted cyclopentadienes and their complexation reactions"